LEXICON PHARMACEUTICALS, INC. Long-term Debt and Lease Obligation
LEXICON PHARMACEUTICALS, INC. (LXRX) had Long-term Debt and Lease Obligation of $5.48 million as of 2023-06-30, per its 10-Q filed 2023-08-04.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtAndCapitalLeaseObligations · last filed 2023-08-04
- 2023-06-30: Long-term Debt and Lease Obligation $5.48M.
- 2023-03-31: Long-term Debt and Lease Obligation $5.45M.
- 2022-12-31: Long-term Debt and Lease Obligation $5.40M; Long-term Debt and Lease Obligation as first filed $5.42M.
- 2022-09-30: Long-term Debt and Lease Obligation $5.44M.
| Period end | Long-term Debt and Lease Obligation | Long-term Debt and Lease Obligation as first filed |
|---|---|---|
| 2023-06-30 | $5.48M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $5.45M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $5.40M 10-Q · filed 2023-08-04 | $5.42M 10-K · filed 2023-03-03 |
| 2022-09-30 | $5.44M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $1.00M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $1.10M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $1.20M 10-K · filed 2023-03-03 | $1.19M 10-K · filed 2022-03-10 |
| 2021-09-30 | $1.48M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $1.62M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $1.72M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $611.00K 10-K · filed 2021-03-12 | |
| 2019-12-31 | $1.10M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |